OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT.


Journal

Minerva cardiology and angiology
ISSN: 2724-5772
Titre abrégé: Minerva Cardiol Angiol
Pays: Italy
ID NLM: 101776555

Informations de publication

Date de publication:
Aug 2023
Historique:
medline: 14 7 2023
pubmed: 28 2 2023
entrez: 27 2 2023
Statut: ppublish

Résumé

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach. OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization. A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%. A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.

Sections du résumé

BACKGROUND BACKGROUND
In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.
METHODS METHODS
OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.
RESULTS RESULTS
A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.
CONCLUSIONS CONCLUSIONS
A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.

Identifiants

pubmed: 36847434
pii: S2724-5683.22.06144-0
doi: 10.23736/S2724-5683.22.06144-0
doi:

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

431-437

Auteurs

Mario Iannaccone (M)

Division of Cardiology, San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy - mario.iannaccone@hotmail.it.

Ovidio DE Filippo (O)

Division of Cardiology, Città della Salute e Scienza, University of Turin, Turin, Italy.

Andrea Montabone (A)

Division of Cardiology, Città della Salute e Scienza, University of Turin, Turin, Italy.

Giorgio Marengo (G)

Division of Cardiology, Città della Salute e Scienza, University of Turin, Turin, Italy.

Ludovica Maltese (L)

Division of Cardiology, Sant'Andrea di Vercelli Hospital, ASL VC, Vercelli, Italy.

Fabrizio Ugo (F)

Division of Cardiology, Sant'Andrea di Vercelli Hospital, ASL VC, Vercelli, Italy.

Giorgio Quadri (G)

Division of Cardiology, Ospedale degli Infermi, ASL TO 3, Rivoli, Turin, Italy.

Maro Mennuni (M)

Division of Cardiology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.

Gioel G Secco (GG)

Division of Cardiology, Ss. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.

Vittorio Taglialatela (V)

Division of Cardiology, Hospital of Chivasso, ASL TO4, Chivasso, Turin, Italy.

Sebastian Cinconze (S)

Division of Cardiology, Croce e Carle Hospital, Cuneo, Italy.

Claudio Moretti (C)

Division of Cardiology, Hospital of Chivasso, ASL TO4, Chivasso, Turin, Italy.

Alessandra Truffa (A)

Division of Cardiology, Cardinal Massaia Hospital, Asti, Italy.

Alfonso Gambino (A)

Division of Cardiology, Hospital of Moncalieri, ASL TO3 Moncalieri, Moncalieri, Turin, Italy.

Giacomo Boccuzzi (G)

Division of Cardiology, San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy.

Vincenzo Infantino (V)

Division of Cardiology, Hospital of Ciriè, ASL TO4, Ciriè, Turin, Italy.

Federico Conrotto (F)

Division of Cardiology, Città della Salute e Scienza, University of Turin, Turin, Italy.

Alessandro Lupi (A)

Division of Cardiology, Hospital of Domodossola, Domodossola, Verbano-Cusio-Ossola, Italy.

Ferdinando Varbella (F)

Division of Cardiology, Ospedale degli Infermi, ASL TO 3, Rivoli, Turin, Italy.

Giuseppe Patti (G)

Division of Cardiology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.

Andrea Rognoni (A)

Division of Cardiology, Hospital of Biella, Biella, Italy.

Giuseppe Musumeci (G)

Division of Cardiology, Mauriziano Hospital, Turin, Italy.

Francesco Prati (F)

Centro per la Lotta Contro L'Infarto-CLI Foundation, Rome, Italy.
UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy.

Gaetano M DE Ferrari (GM)

Division of Cardiology, Città della Salute e Scienza, University of Turin, Turin, Italy.

Fabrizio D'Ascenzo (F)

Division of Cardiology, Città della Salute e Scienza, University of Turin, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH